Atreca, a US-based immune-focused medicine developer based on research at Stanford University, completed an oversubscribed $125m series C round today led by an undisclosed existing investor described as a healthcare-focused fund. The round included Tavistock Group’s Boxer Capital unit, Wellington Management Company, Cormorant Asset Management, Aisling Capital, EcoR1 Capital, Redmile Group, Samsara BioCapital and funds…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.